Omidubicel Approval Represents Key Advance for Patients With Blood Cancers Requiring Transplant

Mitchell E. Horwitz, MD, expands on key efficacy and safety data supporting the FDA approval of omidubicel, the significance of this decision for the blood cancer treatment paradigm, and the need for continued investigation of the agent in non-malignant disease and other patient subgroups.

Related Keywords

United States ,Singapore ,North Carolina ,American ,Mitchelle Horwitz ,Suhag Parikh ,Chenyu Lin ,Joanne Kurtzberg ,National Marrow Donor Program Registry ,Duke Cancer Institute ,Duke Health ,North American ,D ,